Why the study?
Do calcium channel blockers and angiotensin-converting enzyme inhibitors improve outcomes in patients after heart transplantation?
Do calcium channel blockers and angiotensin-converting enzyme inhibitors improve outcomes in patients after heart transplantation?
Calcium channel blockers and ACE inhibitors are effective for managing hypertension and improving outcomes related to graft coronary artery disease in heart transplant recipients.
May support CCBs and ACEIs post-transplant; leaves open confirmation by randomized trials.
PURPOSE OF REVIEW: Hypertension, dyslipidemia, and diabetes are very common problems following heart transplantation and may contribute to the development and progression of graft coronary artery disease. This article reviews current data on clinical use of angiotensin-converting enzyme inhibitors and calcium channel blockers in patients who have had heart transplants. RECENT FINDINGS: Angiotensin-converting enzyme inhibitors and calcium channel blockers are established therapy for patients with cardiovascular disease. Use of these medications correlates with decreasing cardiovascular morbidity and mortality. SUMMARY: After heart transplantation, hypertension associated with calcineurin inhibitors can be managed effectively with antihypertensive therapy, but it may require use of more than one antihypertensive agent. Calcium channel blockers and angiotensin-converting enzyme inhibitors have been associated with improved outcome measures in graft coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Rockx et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: